There are nonpharmacological approaches to managing behavioral and psychological symptoms of dementia and the difficulties associated with evaluating and implementing these approaches.

Medical ethics concerns about the use of memory-modulating technologies should not override individual decisions about their use in clinical contexts.

What are insurance, contract, and criminal law implications of detecting Alzheimer’s disease early?

Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.

Viewing dementia as a distinct disease promotes funding for research but may stigmatize those who have dementia and lead to disinvestment in caregiving.

Neuroscience should be at the core of a sound sleep health curriculum, especially in early classroom-based medical education. 

Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab.

Neuromodulation has ethical implications for self-identity and public communication of scientific findings.

The Bioethics Commission’s recommendations to include research participants with impaired consent capacity provide an ethical foundation for neuroscience.